The 5xFAD mouse is one of the most widely used transgenic mouse models of Alzheimer's disease. Developed by Oakley et al. in 2006[1], it co-expresses five familial AD mutations in human APP and PSEN1 genes, producing rapid and robust amyloid-beta pathology with plaque onset as early as 2 months of age. This makes it one of the fastest-acting amyloid models available.
The model is particularly valuable for studying amyloid-driven neurodegeneration, neuroinflammation, and synaptic dysfunction. While it lacks robust neurofibrillary tangle formation (unlike the 3xTG-AD model), its rapid phenotype enables efficient therapeutic testing[2].
The 5xFAD transgenic construct expresses human APP with three Swedish/Florida/London mutations combined with two PSEN1 mutations[1:1]:
| Gene | Mutation | Position | Effect |
|---|---|---|---|
| APP | Swedish (K670N/M671L) | 670/671 | Enhanced β-secretase cleavage, 3-4× more Aβ |
| APP | Florida (I716V) | 716 | Increased Aβ production |
| APP | London (V717I) | 717 | Altered γ-secretase processing |
| PSEN1 | M146L | 146 | Increased Aβ42/Aβ40 ratio |
| PSEN1 | L286V | 286 | Increased Aβ42/Aβ40 ratio |
The APP transgene is driven by the mouse Thy1 promoter, providing neuron-specific expression. The combination of five FAD mutations dramatically shifts APP processing toward Aβ42 production, driving rapid pathology.
The 5xFAD line is maintained on a C57BL/6J background. Mice are typically heterozygous for the transgene, as homozygous mice show more severe phenotypes and reduced viability. The model is available from The Jackson Laboratory (strain #006554).
The 5xFAD model demonstrates exceptionally rapid amyloid plaque formation[1:2]:
Plaque distribution follows a characteristic pattern:
5xFAD mice exhibit progressive neuronal loss[2:1]:
The synaptic pathology precedes obvious plaque deposition, suggesting soluble oligomers may be toxic even before plaque formation.
Astrocytic and microglial activation accompanies amyloid deposition[3]:
The 5xFAD model shows limited endogenous tau pathology[7]:
Crossing 5xFAD with human tau-expressing mice dramatically accelerates both Aβ and tau pathology, creating a more comprehensive dual-pathology model[8].
Memory impairment in 5xFAD mice follows a progressive course[9]:
Motor deficits appear later than cognitive changes:
5xFAD mice exhibit early hippocampal network dysfunction before significant amyloid plaque deposition[11]. Soluble Aβ oligomers — not plaques — drive early cognitive impairment.
Key electrophysiological changes[12]:
5xFAD neurons show significant mitochondrial abnormalities[13]:
5xFAD mice exhibit excessive microglial phagocytosis of synapses via complement-mediated pathways[5:1]:
5xFAD mice parallel human AD biomarker trajectories[14]:
5xFAD mice show impaired neurovascular function[15]:
The 5xFAD model is extensively used for drug development:
The model enables validation of biomarkers:
Researchers use 5xFAD to investigate:
| Age | Stage | Phenotype |
|---|---|---|
| 1-2 months | Pre-plaque | Baseline behavior, subtle Aβ |
| 2-4 months | Early plaque | Subtle cognitive deficits |
| 4-6 months | Established | Clear cognitive deficits, synaptic loss |
| 6-9 months | Advanced | Severe pathology, gliosis |
| 9-12 months | Late | Maximal pathology, neuronal loss |
| Model | Transgenes | Plaque Onset | Tangles | Cognitive Deficit |
|---|---|---|---|---|
| 5xFAD | APP×3 + PSEN1×2 | 2 months | Minimal | 4-6 months |
| 3xTG-AD | APP + TAU + PSEN1 | 6 months | 12 months | 6-10 months |
| APP/PS1 | APP + PSEN1 | 6-9 months | No | 8-12 months |
| Tg2576 | APP Swedish | 9-12 months | No | 12-15 months |
Oakley H, Carr SL, Cronise C, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations. Journal of Neuroscience. 2006. ↩︎ ↩︎ ↩︎ ↩︎
Hong S, Venero JL, Cox CL, et al. Synaptic dysfunction in the 5xFAD mouse model. Cell Reports. 2016. ↩︎ ↩︎ ↩︎
Boza-Serrano A, Tarragó MS, Deierborg T. The role of microglia in the 5xFAD mouse model. Glia. 2019. ↩︎ ↩︎ ↩︎
Fan L, Mao C, Wang Z, et al. Astrocyte responses in 5xFAD mice. Glia. 2020. ↩︎ ↩︎
Shi Q, Chowdhury EH, Colton SL, et al. Synaptic pruning deficits in 5xFAD. Neuron. 2022. ↩︎ ↩︎ ↩︎
DeMars KM, Gower E, Yang J, et al. 5xFAD neuroinflammation progression. Journal of Neuroinflammation. 2021. ↩︎ ↩︎
Jawhar S, Trawicka A, Jarde C, et al. Rapid accumulation of endogenous tau in the brains of 5xFAD mice. Journal of Alzheimer's Disease. 2011. ↩︎ ↩︎
Shi Y, Yamada K, Liddelow SA, et al. Human wild-type tau expression accelerates Abeta pathology in 5xFAD mice. Acta Neuropathologica. 2018. ↩︎ ↩︎
Crews L, Mobley W, Tsuji J, et al. Neurocognitive decline in 5xFAD mice. Journal of Neuroscience. 2010. ↩︎ ↩︎
McAlinn JR, Koshy V, Ebrahimi S, et al. Novel object recognition deficits in 5xFAD mice. Neurobiology of Aging. 2017. ↩︎ ↩︎
Zhao J, Fu Y, Yasvoina J, et al. 5xFAD mice exhibit early hippocampal network dysfunction. Journal of Neuroscience. 2017. ↩︎ ↩︎
Kort J, Zhang H, Grin'kina N, et al. EEG abnormalities in 5xFAD mice. Alzheimer's & Dementia. 2020. ↩︎ ↩︎ ↩︎
Song G, Li L, Shen L, et al. Mitochondrial dysfunction in 5xFAD neurons. Cell Death & Disease. 2019. ↩︎ ↩︎
Cruchaga C, Del-Aguila JL, Fernandez MV, et al. CSF biomarkers in 5xFAD mice correlate with brain pathology. Brain. 2020. ↩︎
Hu N, Wu J, Liu S, et al. Neurovascular dysfunction in 5xFAD mice. Journal of Cerebral Blood Flow & Metabolism. 2018. ↩︎ ↩︎
Wang S, Mastrogiacomo R, Wang R, et al. TREM2 deficiency in 5xFAD mice. Journal of Neuroscience. 2022. ↩︎ ↩︎
Schelle J, Wegenast-Braun BM, Frick L, et al. Abeta oligomer dynamics in 5xFAD brains. Nature Communications. 2019. ↩︎ ↩︎